In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.Listen as he discusses:The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV careOptions in people with multiclass resistanceStudies of agents with novel mechanisms of action:BRIGHTE (fostemsavir)TMB-301/-311 (ibalizumab)CAPELLA (lenacapavir) FacultyGregory Huhn, MD, MPHTM,Interim Chief, Division of Infectious DiseasesSenior Director of HIV ServicesCook County HIV Integrated ProgramsInterim Medical Director, The RMR CORE CenterProfessor, Division of Infectious DiseasesRush University Medical CenterChicago, IllinoisFollow along with the slides.https://bit.ly/4fHmxg5Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related